Cytochrome p-450 polymorphisms and response to clopidogrel.

@article{Mega2009CytochromePP,
  title={Cytochrome p-450 polymorphisms and response to clopidogrel.},
  author={J. Mega and S. Close and S. Wiviott and Lei-Bin Shen and R. Hockett and J. Brandt and Joseph R. Walker and E. Antman and W. Macias and E. Braunwald and M. Sabatine},
  journal={The New England journal of medicine},
  year={2009},
  volume={360 4},
  pages={
          354-62
        }
}
BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. METHODS We tested the association between functional genetic variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects. We then examined the association between these genetic… Expand

Paper Mentions

Observational Clinical Trial
The hypothesis of this study is that "the poor metabolizer or intermediate metabolizer of the cytochrome P450 2C19 genotype in patients with acute ischemic stroke is associated with… Expand
ConditionsAcute Ischemic Stroke
InterventionDrug
Interventional Clinical Trial
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with… Expand
ConditionsMyocardial Infarction, STEMI
InterventionGenetic
Interventional Clinical Trial
The purpose of this study is to evaluate whether patients post PCI receiving clopidogrel who are carriers of at least one CYP 2C19 loss-of-function allele may achieve improved… Expand
ConditionsAcute Coronary Syndrome
InterventionDrug
Cytochrome P 450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes
Background—Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of reduced-functionExpand
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
TLDR
Common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel, and these pharmacogenetic findings are in contrast to observations with clopidogrel. Expand
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
TLDR
Intermediate and poor metabolizing CYP2C19 polymorphism is associated with reduced clopidogrel antiplatelet activity in patients with cerebrovascular disease. Expand
Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
TLDR
The impact of cytochrome P450 enzymes genetic variation and CYP450 pathway drug-drug interactions in pharmacological and clinical response to clopidogrel are discussed. Expand
Cytochrome P450 2C19 genotyping for clopidogrel response - the state of play.
TLDR
While meta-analyses consistently observe an association of CYP2C19 genotype with clopidogrel responsiveness, an association with cardiovascular events is less clear, which may explain the lack of association identified in large cardiovascular event studies. Expand
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
TLDR
Based on the genetic analysis in a high-risk population of acute MI patients with interventional treatment and continuous clopidogrel therapy, a protective effect for carriers of an increased-function CYP2C19*17 T-allele with significantly lower rates of TLR and MACE is found. Expand
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
TLDR
The role of pharmacogenetics and drug interactions in determining variability in response to clopidogrel is summarized. Expand
Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
TLDR
Findings indicated that only CYP2C19*2 and *3 alleles had an influence on clopidogrel resistance and there was no evidence of gene-gene interaction or LD between CYP 2C19 and PON1 polymorphisms on ADP-induced platelet aggregation. Expand
Routine genotyping of patients on clopidogrel: Why the resistance?
TLDR
It is reasonable to ask why genomic testing should not be used routinely to guide the choice of antiplatelet therapy, as Rath and colleagues report in this issue of the Journal. Expand
Genetic and nongenetic factors influencing the response to clopidogrel
TLDR
A genetic test to identify potential responders to clopidogrel might be useful, but the use of such tests is currently limited because they focus mainly on CYP2C19 loss-of-function alleles, and there is no empirical evidence yet for genotype-guided clopIDogrel therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
TLDR
The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopsinogrel resistance in the clinical setting. Expand
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
TLDR
The IVS10+12G>A polymorphism of the CYP3A4 gene modulates platelet activation in patients treated with clopidogrel and may therefore contribute to clopIDogrel response variability. Expand
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
TLDR
Multivariable analysis showed that the CYP3A5 polymorphism was a predictor of atherothrombotic events in clopidogrel users, which may be associated with worse outcomes in patients with the non-expressor genotype who are given clopIDogrel after coronary angioplasty and implantation of bare-metal stents. Expand
2 C 19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
The capacity of clopidogrel to inhibit ADPinduced platelet aggregation shows wide intersubjectvariability.Todeterminewhether frequent functional variants of genes coding for candidate cytochrome P450Expand
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
TLDR
Patients carrying at least one CYP2C19*2 allele are more prone to high-on clopidogrel platelet reactivity, which is associated with poor clinical outcome after coronary stent placement, and the effect of ClopidOGrel Loading and Risk of PCI is investigated. Expand
The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
TLDR
It is clear that the CYP2C19 genotype affects the plasma levels of clopidogrel and modulates the antiplatelet effect of clopsinogrel. Expand
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
TLDR
CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite, which is associated with reduced IPA. Expand
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
TLDR
Genotyping for the common alleles of CYP2C19 before initiating PPIs for the treatment of reflux disease and H. pylori infection is a cost effective tool to determine appropriate duration of treatment and dosage regimens and, because of its narrow therapeutic range, genotyping of CYPs in addition to CYP1C9 may be needed to optimise the dosage of phenytoin. Expand
Influence of cytochrome P 450 polymorphisms on drug therapies : Pharmacogenetic , pharmacoepigenetic and clinical aspects
The polymorphic nature of the cytochrome P450 (CYP) genes affects individual drug response and adverse reactions to a great extent. This variation includes copy number variants (CNV), missenseExpand
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
TLDR
It is concluded that the pharmacogenetic knowledge regarding CYP polymorphism now developed to a stage where it can be implemented in drug development and in clinical routine for specific drug treatments, thereby improving the drug response and reducing costs for drug treatment. Expand
...
1
2
3
4
5
...